Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Tesaro, Inc.
Sotio Biotech Inc.
Pfizer
Alaunos Therapeutics
Incyte Corporation
Mural Oncology, Inc
Masonic Cancer Center, University of Minnesota
Herlev Hospital
M.D. Anderson Cancer Center
Numab Therapeutics AG
Mayo Clinic
Pfizer
Thomas Jefferson University
NextCure, Inc.
M.D. Anderson Cancer Center
Elevation Oncology
North Eastern German Society of Gynaecological Oncology
Deciphera Pharmaceuticals, LLC
Astellas Pharma Inc
Five Prime Therapeutics, Inc.
Pfizer
AbbVie
NantCell, Inc.
University of Pittsburgh
NantCell, Inc.
ModernaTX, Inc.
Pfizer
NextCure, Inc.
ADC Therapeutics S.A.
Sumitomo Pharma America, Inc.
Pfizer
M.D. Anderson Cancer Center
University of Washington
CytomX Therapeutics
University of Washington
Eastern Cooperative Oncology Group
Brown University
Ludwig Institute for Cancer Research
pharmaand GmbH
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Cantonal Hospital of St. Gallen
National Cancer Institute (NCI)
Eisai Inc.
Pfizer
Morphotek
Marker Therapeutics, Inc.
Tesaro, Inc.